JPH02101022A - 糖尿病治療用医薬組成物 - Google Patents

糖尿病治療用医薬組成物

Info

Publication number
JPH02101022A
JPH02101022A JP1207057A JP20705789A JPH02101022A JP H02101022 A JPH02101022 A JP H02101022A JP 1207057 A JP1207057 A JP 1207057A JP 20705789 A JP20705789 A JP 20705789A JP H02101022 A JPH02101022 A JP H02101022A
Authority
JP
Japan
Prior art keywords
insulin
formula
arg
pharmaceutical composition
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1207057A
Other languages
English (en)
Japanese (ja)
Inventor
Michael Doerschug
ミヒアエル・デルシュク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of JPH02101022A publication Critical patent/JPH02101022A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP1207057A 1988-08-13 1989-08-11 糖尿病治療用医薬組成物 Pending JPH02101022A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3827533.3 1988-08-13
DE3827533A DE3827533A1 (de) 1988-08-13 1988-08-13 Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Publications (1)

Publication Number Publication Date
JPH02101022A true JPH02101022A (ja) 1990-04-12

Family

ID=6360797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1207057A Pending JPH02101022A (ja) 1988-08-13 1989-08-11 糖尿病治療用医薬組成物

Country Status (18)

Country Link
US (1) US5177058A (https=)
EP (1) EP0357978B1 (https=)
JP (1) JPH02101022A (https=)
KR (1) KR900002801A (https=)
AT (1) ATE75945T1 (https=)
AU (1) AU621648B2 (https=)
CA (1) CA1332354C (https=)
DE (2) DE3827533A1 (https=)
DK (1) DK395689A (https=)
ES (1) ES2039773T3 (https=)
FI (1) FI95202C (https=)
GR (1) GR3005326T3 (https=)
HU (1) HU203670B (https=)
IE (1) IE61266B1 (https=)
NO (1) NO178914C (https=)
NZ (1) NZ230280A (https=)
PT (1) PT91420B (https=)
ZA (1) ZA896149B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213727A (ja) * 1993-04-07 2006-08-17 Scios Inc ペプチドの持続放出
JP2011006428A (ja) * 2005-12-28 2011-01-13 Novo Nordisk As インスリン組成物および組成物の製造方法
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE4024434A1 (de) * 1990-08-01 1992-02-13 Fresenius Ag Vorrichtung zur ultrafiltrationskontrolle bzw. ultrafiltrationsregelung bei blutreinigungsverfahren
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CZ2004710A3 (cs) * 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1620465A2 (en) * 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
CA2531988C (en) * 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
RU2453332C2 (ru) * 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143591A (en) * 1936-09-26 1939-01-10 Univ Alberta Therapeutic preparation and process of making and using it
US2354211A (en) * 1940-07-02 1944-07-25 Burroughs Wellcome Co Insulin preparation
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3334407A1 (de) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213727A (ja) * 1993-04-07 2006-08-17 Scios Inc ペプチドの持続放出
JP2011006428A (ja) * 2005-12-28 2011-01-13 Novo Nordisk As インスリン組成物および組成物の製造方法
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12226458B2 (en) 2018-06-26 2025-02-18 Novo Nordisk A/S System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Also Published As

Publication number Publication date
NO893239L (no) 1990-02-14
US5177058A (en) 1993-01-05
AU621648B2 (en) 1992-03-19
DK395689D0 (da) 1989-08-11
EP0357978B1 (de) 1992-05-13
FI95202B (fi) 1995-09-29
FI893783L (fi) 1990-02-14
NO178914C (no) 1996-07-03
CA1332354C (en) 1994-10-11
PT91420B (pt) 1995-05-04
NO178914B (no) 1996-03-25
ZA896149B (en) 1990-04-25
NZ230280A (en) 1991-09-25
FI893783A0 (fi) 1989-08-10
HUT50443A (en) 1990-02-28
ATE75945T1 (de) 1992-05-15
IE61266B1 (en) 1994-10-19
DE3827533A1 (de) 1990-02-15
KR900002801A (ko) 1990-03-23
HU203670B (en) 1991-09-30
ES2039773T3 (es) 1996-07-16
FI95202C (fi) 1996-01-10
IE892594L (en) 1990-02-13
DE58901401D1 (de) 1992-06-17
NO893239D0 (no) 1989-08-11
EP0357978A1 (de) 1990-03-14
DK395689A (da) 1990-02-14
AU3951489A (en) 1990-02-15
PT91420A (pt) 1990-03-08
GR3005326T3 (https=) 1993-05-24

Similar Documents

Publication Publication Date Title
JPH02101022A (ja) 糖尿病治療用医薬組成物
ES2405994T3 (es) Soluciones estabilizadas de teriparatide
AU2003238862B9 (en) Formulations for amylin agonist peptides
EP0904099B1 (en) Pharmaceutical formulation containing human growth hormone, histidine and a non-ionic detergent
JP4353544B2 (ja) アミリン作動薬ペプチド用製剤
US7205277B2 (en) Zinc-free and low-zinc insulin preparations having improved stability
CN102274492B (zh) 骨合成代谢蛋白质的药物递送方法
JP5675799B2 (ja) 遅効性インスリン製剤
TW201100093A (en) Preparation comprising insulin, nicotinamide and an amino acid
JP4123309B2 (ja) 鼻内投与のための薬学的非無機塩類液剤
JP2012233003A (ja) 単量体インスリン及びアシル化インスリンを含む可溶性製剤
JPH0196137A (ja) 真性糖尿病の治療
US6150331A (en) Human growth hormone-containing aqueous pharmaceutical composition
US5028587A (en) Mixed crystals of insulin and insulin derivatives
JP2005538068A (ja) 高濃度のヒト成長ホルモン（ｈＧＨ）とフェノールを含有する液剤
JPH05331071A (ja) カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
EP1414431B1 (en) AMINO-ACID-BASED therapeutic COMPOSITIONS, FOR THE HEALING AND/OR MENDING OF WOUNDS AND LESIONS, IN PARTICULAR IN THE OPHTHALMIC FIELD
JPH05170664A (ja) 安定なペプチド医薬組成物
JPS6237017B2 (https=)